A fixed-dose combination topical preparation containing a corticosteroid (Beclometasone), an aminoglycoside antibiotic (Neomycin), and an imidazole antifungal (Clotrimazole). It is primarily indicated for the treatment of mixed inflammatory, bacterial, and fungal skin infections, particularly in conditions like infected eczema, dermatitis, and intertrigo. This combination provides broad-spectrum coverage against common skin pathogens while reducing inflammation and pruritus.
Adult: Apply a thin layer to the affected area 2 to 3 times daily. Duration should be limited to 1-2 weeks. Maximum weekly amount: Not more than 50g cream per week for adults.
Note: 1. Wash and dry the affected area gently. 2. Take a small amount of cream on clean fingertips. 3. Apply a thin film and rub in gently until absorbed. 4. Wash hands after application unless hands are the treated area. 5. Do not cover with airtight dressings (occlusion) unless specifically advised by a doctor, as it increases absorption and side effects. 6. Avoid contact with eyes, nose, mouth, and other mucous membranes.
The combination works synergistically: Beclometasone suppresses inflammation, immune response, and pruritus; Neomycin inhibits protein synthesis in susceptible gram-positive and gram-negative bacteria; Clotrimazole inhibits ergosterol synthesis in fungal cell membranes.
Pregnancy: Category C (US FDA). Topical corticosteroids, including Beclometasone, can be absorbed in small amounts. Use only if clearly needed and for the shortest duration possible. Avoid large areas or potent occlusion. Neomycin and Clotrimazole topical use is generally considered low risk, but systemic absorption should be minimized.
Driving: No effect on driving ability.
| Other Topical Corticosteroids | Additive risk of local and systemic side effects (atrophy, HPA suppression). | Major |
| Systemic Aminoglycosides (e.g., Gentamicin, Amikacin) | Increased risk of ototoxicity and nephrotoxicity if Neomycin is absorbed systemically. | Major |
| Loop Diuretics (e.g., Furosemide) | Potentiates the ototoxic risk of Neomycin. | Moderate |
| Other Topical Agents (e.g., Salicylic Acid, Retinoids) | May increase skin irritation and penetration of active ingredients. | Moderate |
| CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Clarithromycin) | May increase systemic levels of Beclometasone by inhibiting its metabolism, increasing steroid side effects. | Moderate |
Same composition (Beclometasone (0.025% w/w) + Neomycin (3500u/1g) + Clotrimazole (1% w/w)), different brands: